Grove Bank & Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Grove Bank & Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-134	Closed	-$9.47K	–	861
2025 Q1	$9.47K	Buy	+134	New	+$9.02K	﹤0.01%	591
2018 Q1	–	Sell	-72	Closed	-$6K	–	193
2017 Q4	$6K	Sell	72 -239	-77%	-$20.8K	﹤0.01%	471
2017 Q3	$29K	Sell	311 -642	-67%	-$56.7K	0.01%	357
2017 Q2	$87K	Buy	953 +620	+186%	+$56.4K	0.06%	198
2017 Q1	$29K	Buy	333 +316	+1,859%	+$28.1K	0.02%	262
2016 Q4	$1K	Buy	+17	New	+$1.46K	﹤0.01%	570
2016 Q3	–	Sell	-23	Closed	-$2K	–	248
2016 Q2	$2K	Buy	+23	New	+$1.96K	﹤0.01%	260

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grove Bank & Trust's BMRN Position: Q2 2025 in Review

Grove Bank & Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 134 shares — an estimated $9.47K sold.

Grove Bank & Trust first reported a position in BMRN in Q2 2016 and held it in 7 quarters. The position peaked at $87K in Q2 2017. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Grove Bank & Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Grove Bank & Trust sold 134 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $9.47K.
Grove Bank & Trust first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 7 quarters.
Grove Bank & Trust's BioMarin Pharmaceuticals position peaked at $87K in Q2 2017.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Grove Bank & Trust's 13F filing for Q2 2025, filed 11 Jul 2025.